Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Immunol Cell Biol. 2013 Apr 30;91(6):435–440. doi: 10.1038/icb.2013.17

Figure 3. NKG2D CAR T cell therapy confers protection against a NKG2D ligand-negative tumor cell re-challenge.

Figure 3

Mice injected with ID8/GFP tumor cells received three doses of chNKG2D T cells 5, 7, and 9 weeks post-tumor inoculation, and these mice became long-term tumor-free survivors. (a) Tumor-surviving mice were re-challenged with 2 × 106 ID8/GFP-shRae1 cells i.p. 250 days after ID8/GFP injection. After 8 weeks, the number of solid tumors and tumor cells in ascites were assessed (***, p < 0.001 vs. naïve). (b) Splenocytes from tumor-surviving mice who did not receive a tumor re-challenge were isolated (at 250 days) and tested for production of IFN-γ in response to ID8, ID8/GFP-shRae1, RMA, and RMA-Rae1 (RMA-R) cells (***, p < 0.001 vs. naïve).